Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan-Meier survival curves

BMC Medical Research Methodology

Volumn 12, Issue , 2012, Pages

  Guyot, Patricia ^a,b   Ades, A E ^a   Ouwens, Mario ^b   Welton, Nicky ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MAPI GROUP   (Netherlands)

Author keywords

algorithm; Cost Effectiveness Analysis; Health Technology Assessment; Individual Patient Data; Kaplan Meier; life table; Survival analysis

Indexed keywords

EID: 84856397828     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-12-922297116     Document Type: Article

References (31)

1. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c869.
2. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in medicine 1991, 10:1665-1677.
3. Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP: Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 2005, 21(1):119-25. (Pubitemid 40229377)
4. Dear KBG: Alternative generalized least squares for meta-analysis of survival data at multiple time. Biometrics 1994, 50:989-1002.
5. Arends L, Hunink M, Stijnen T: Meta-analysis of summary survival curve. Statistics in medicine 2008, 27:4381-4396.
6. Fiocco M, Putter H, van Houwelingen JC: Meta-analysis of pairs of survival curves under heterogeneity: a Poisson correlated gamma-frailty approach. Statistics in medicine 2009, 28:3782-3797.
7. Parmar MKB, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in medicine 1998, 17:2815-2834. (Pubitemid 28562978)
8. Ouwens MJNM, Philips Z, Jansen JP: Network meta-analysis of parametric survival curves. Research Synthesis Methods 2010, 1(3-4):258-271.
9. Jansen JP: Network meta-analysis of survival data with fractional polynomials. BMC Medical Research Methodology 2011, 11:61.
10. Earle C, Wells G: An Assessment of Methods to Combine Published Survival Curves. Medical Decision Making 2000, 20:104-111. (Pubitemid 30036269)
11. Williamson PR, Tudur Smith C, Hutton JL, Marson AG: Aggregate data meta-analysis with time-to-event outcomes. Statistics in medicine 2002, 21:3337-3351. (Pubitemid 35314654)
12. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2006, 354:567-78. (Pubitemid 43209104)
13. Guyot P, Welton NJ, Ouwens MJNM, Ades AE: Survival time outcomes in randomised controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. Value In Health 2011, 14(5):640-6.
14. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick D: Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. Journal of evaluation in clinical practice 2000, 6(2):205-214. (Pubitemid 30615011)
15. Stewart LA, Tierney JF: To IPD or not to IPD? : Advantages and disadvantages of systematic reviews using individual patient data. Evaluation and the Health Professions 2002, 25:76.
16. Bellera CA, MacGrogan G, Debled M, Tunon de Lara C, Brouste V, Mathoulin-Pélissier S: Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Medical Research Methodology 2010, 10:20.
17. Collett D: Modelling Survival Data in Medical Research. Boca Raton: Chapman & Hall/CRC;, Second 2003.
18. Cox C: The generalized F distribution: an umbrella for parametric survival analysis. Stat Med 2008, 27:4301-12.
19. McDonald JB, Xub YJ: A generalization of the beta distribution with applications. Journal of Econometrics 1995, 66:133-152.
20. Royston P, Parmar MKB: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med 2002, 21:2175-97. (Pubitemid 34830755)
21. Morden J, Lambert P, Latimer N: Assessing methods for dealing with treatment switching in randomised clinical trials. 2010 [http://www. nicedsu.org.uk/Crossover%20and%20survival%20-%20final%20DSU%20report.pdf].
22. van Houwelingen HC, van de Velde CJH, Stijnen T: Interim analysis on survival data: its potential bias and how to repair it. Statistics in medicine 2005, 24:2823-2835. (Pubitemid 41358711)
23. Hunink MGM, Wong JB: Meta-analysis of failure-time data with adjustment for covariates. Medical decision Making 1994, 14:59-70. (Pubitemid 24032683)
24. Shore T, Nelson N, Weinerman B: A meta-analysis of stages I and II Hodgkin's disease. Cancer 1990, 65:1155-60. (Pubitemid 20072051)
25. Voest EE, Van Houwelingen JC, Neijt JP: A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log(relative risk)) as main objectives. European Journal of Cancer and Clinical Oncology 1989, 25:711-20. (Pubitemid 19096441)
26. Rothman K, Greenland S, Lash TL: Modern epidemiology. Lippincott Williams & Wilkins;, Third 2008.
27. Van Oers MH, Klasa R, Marcus RE, Wolf M, Gascoyne RD, Jack A, Van'tVeer M, Vranovsky A, Holte H, van Glabbeke M, Teodorovic I, Rozewicz C, Hagenbeek A: Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III study. Blood 2006, 108:3295-3301. (Pubitemid 44794222)
28. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. JNCI Cancer Spectrum 2005, 97:1262-1271. (Pubitemid 41535367)
29. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Sheperd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MKB, Stephens RJ: FOCUS Trial Investigators. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007, 370(9582):143-52, Erratum in: Lancet. 2007 Aug 18; 370(9587):566. (Pubitemid 47042894)
30. Pan J-N: Evaluating the Gauge repeatability and reproducibility for different industries. Quality & Quantity 2006, 40:499-518. (Pubitemid 44214402)
31. Wang F-K, Li E: Confidence intervals in repeatability and reproducibility using the Bootstrap method. Total quality management 2003, 14(3):341-354. (Pubitemid 36989529)